Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

Good news on COVID-19 front
October 2020
SHARING OPTIONS:

AUSTIN, Texas—August saw XBiotech Inc. announce that thanks to a collaboration with BioBridge Global, it had identified True Human antibodies that could potentially serve as a candidate therapy against SARS-CoV-2. The antibodies were generated from convalescent plasma samples from patients who had contracted COVID-19 but recovered quickly without serious illness. BioBridge Global applied XBiotech's COVID-19 screening technology to identify blood donors who had recovered, and supplied XBiotech with blood samples. XBiotech has now identified several True Human antibodies that are capable of simultaneously blocking the infectious ability of SARS-CoV-2 and boosting the human immune system's ability to remove the virus.
 
“COVID-19 has resulted in an unprecedented impact on our community. We are pleased to be able to utilize our unique discovery technology to rapidly identify natural human immunity—in the form of True Human antibodies—that can potentially be used to treat the virus infection in humans,” remarked Dr. Galina Kuzmicheva, XBiotech’s principal scientist.

Back



PAGE UTILITIES


CONTACT US
DDNEWS
1000 N West Street, Suite 1200,
Wilmington, Delaware, 19801
Ph: 888-781-0328 |  Fax: 705-528-0270
 
© Copyright 2020 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.